Victoria’s pathology overhaul triggers scrutiny over centralisation and cost cutting agenda

Victoria’s overhaul of public pathology services will dismantle the current model of independently operated hospital laboratories and replace it with two centralised pathology networks led by Melbourne Health and Bayside Health.

The reform has already generated unease among senior health leaders, with concerns emerging around cost reduction measures, employment security, and the operational impact of moving specialist pathology services away from individual hospitals and into larger centralised systems.

Among the concerns has been the proposed delisting of onsite pathology services at Peter MacCallum Cancer Centre, Australia’s only public hospital solely dedicated to cancer treatment, research, and care. Senior executives at Peter Mac have raised concerns about transferring its pathology operations to Melbourne Health, arguing that the change will affect the close integration between pathology specialists, clinicians, and cancer care teams that underpin complex oncology treatment.

Early operational challenges have already emerged as a result of the overhaul, with Monash Health reporting delays in patient pathology results following the transition to a new pathology information platform, PathNet.

The reforms have attracted criticism from Georgie Crozier MP, Shadow Minister for Health, who has accused the Victorian Labor government of pursuing a model of hospital consolidation that concentrates authority within centralised structures while weakening the influence of local health services and communities. She argued that the amalgamation risks reducing local decision-making power and could contribute to declining service responsiveness.

The experience of NSW Health Pathology has been cited as an example of the potential for cost cutting through a more integrated model. The reforms reduced spending by $280 million on pathology goods and services over 10 years, equating to a 14% reduction in real terms through more aggressive procurement practices and benchmarking of goods and service utilisation to reduce expenditure. Savings achieved in regional and rural areas were even higher, with a 19% reduction in charges in real terms.

Under Victoria’s initial transition arrangements for the consolidation of public pathology services, participation in the two pathology networks will be restricted to health services approved by the Minister for Health. During this transitional phase, any significant changes to the operating model, including alterations to service delivery arrangements, will require approval from the Department of Health.

Once the pathology networks are established and fully operational, the Department of Health will introduce ongoing performance monitoring processes for each network. The lead health services responsible for the networks will be required to develop and share annual workplans and project budgets, provide quarterly progress reports, and maintain rolling financial reporting requirements.

As the pathology networks mature, responsibility for governance arrangements, service delivery decisions, and other operational matters will progressively shift to the discretion of the lead health services. However, continued consultation with the Department of Health will remain a requirement.

The department will collect a broad range of performance and financial data aligned with the reform’s cost-efficiency objectives and will undertake a formal evaluation of each pathology network and the broader reform program within three years of the networks’ establishment, followed by reviews at least every six years thereafter.

While the government has positioned the restructuring as a necessary modernisation of Victoria’s pathology system, critics argue the reforms represent a broader centralisation agenda that prioritises financial efficiency over clinical independence and local responsiveness to patient care.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.